UMediC Group Berhad (UMC) Announces Second Quarter FY2026 Financial Results: Growth Momentum and Strategic Expansion in Healthcare

Key Financial Highlights for Q2 FY2026

• Revenue: RM13.41 million for Q2 FY2026, up 15.77% year-on-year from RM11.58 million. Cumulative 6-month revenue reached RM27.57 million, a 12% increase from RM24.63 million.
• Profit Before Tax (PBT): RM2.65 million for the quarter, up 7.71% from RM2.46 million in Q2 FY2025. Cumulative 6-month PBT is RM4.94 million (Q2 FY2025: RM4.89 million).
• Net Profit: RM2.45 million for the quarter (Q2 FY2025: RM1.99 million). 6-month cumulative net profit is RM4.30 million (Q2 FY2025: RM3.82 million).
• Profit Attributable to Equity Holders: RM2.00 million for Q2, up from RM1.89 million. For 6 months: RM3.78 million (FY2025: RM3.74 million).
• Earnings Per Share (EPS): Maintained at 0.54 sen for the quarter and 1.01 sen for 6 months. No dilution as there are no convertible securities.

Balance Sheet & Cash Flow Position

• Total Assets: RM102.63 million as at 31 January 2026, up from RM91.22 million at July 2025, driven by increases in property, plant & equipment, inventories, and marketable securities.
• Shareholders’ Funds: Equity attributable to shareholders stands at RM83.90 million, with total equity (including non-controlling interest) at RM85.66 million.
• Borrowings: Jumped to RM6.41 million (previously nil), reflecting new drawdowns for expansion.
• Cash and Bank Balances: RM9.52 million, a decrease from RM11.62 million at financial year-end, primarily due to high capex and investments.
• Capital Commitments: RM1.74 million approved and contracted for property, plant, and equipment purchases, signalling continued investment in capacity expansion.

Segmental Performance

• Manufacturing: This segment drove the revenue growth, contributing RM8.41 million in external revenue and RM2.22 million in segment profit before tax for the period.
• Marketing & Distribution: Generated RM19.16 million in external revenue and RM6.28 million in segment profit before tax.
• Inter-Segment Eliminations: RM4.61 million, reflecting internal transactions between divisions.

Strategic and Operational Highlights

• Expansion Initiatives: UMC continues to invest in expanding its manufacturing capacity, including new cleanroom facilities and acquisition of a new 3-acre industrial land to meet growing global demand. The company has also diversified into laboratory markets and entered the ambulatory care segment with Health Ministry approval to expand its ambulance fleet.
• Healthcare Ecosystem Diversification: UMC is expanding its healthcare ecosystem with its own learning and healthcare centre and through subsidiaries Akiteck and Ateria, is entering medical molding solutions and global trade.
• Cash Flow: Operating cash flows remain positive at RM2.66 million for the half-year, but net cash decreased due to heavy capex (RM8.97 million) and investment in marketable securities.
• IPO Proceeds Fully Utilized: All RM31.11 million raised from the July 2022 IPO have been fully allocated to capital expenditure, working capital, repayment of borrowings, and listing expenses.

Taxation

• Effective Tax Rate: 12.87% for the half-year, significantly below the statutory rate of 24%. This is due to reinvestment allowance incentives and non-taxable grant amortisations, providing a boost to bottom-line profitability.

Outlook and Prospects

• Government Policy Support: The Malaysian government’s increased healthcare allocation (RM46.5 billion for Budget 2026 and RM40.0 billion under the 13th Malaysia Plan through 2030) creates a highly favourable environment for UMC. This supports demand for medical devices, facility upgrades, and digital transformation in healthcare.
• Sector Tailwinds: UMC is strategically positioned to benefit from rising healthcare tourism, growing demand for ambulatory care, and public hospital overcrowding solutions.
• Manufacturing Expansion: Investments in technology and new facilities are expected to underpin long-term growth and drive future earnings.

Shareholder-Relevant and Potentially Price-Sensitive Items

• Borrowings: The significant increase in borrowings (RM6.41 million) reflects a more aggressive growth strategy. Investors should monitor interest costs and balance sheet leverage.
• Full Utilisation of IPO Funds: All proceeds have been deployed, and benefits are expected to flow through in subsequent quarters as expansion projects are completed.
• Tax Incentives: Lower effective tax rate boosts profitability and enhances shareholder value.
• Strong Performance in Manufacturing: The manufacturing segment is the key growth driver, and further expansion in this area could materially enhance future financial performance.
• No Dividend Declared: No dividend has been declared for the current quarter, with cash presumably being retained for expansion.
• No Outstanding Litigation or Corporate Proposals: The company faces no material legal or corporate uncertainties at present.

Conclusion

UMC’s Q2 FY2026 performance reflects robust revenue and profit growth, underpinned by its manufacturing expansion and strategic moves into new healthcare verticals. With strong government policy tailwinds, full deployment of IPO funds, and ongoing investments in capacity and technology, the Group is well-positioned for continued growth. However, the rapid balance sheet expansion—especially the increase in borrowings—should be watched closely for its impact on future earnings and financial risk. The market may react positively to the company’s growth trajectory and sector positioning, but the share price could also be sensitive to execution risks and any changes in government healthcare spending.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult their financial advisors before making investment decisions. The author and publisher are not responsible for any losses incurred based on the information provided above.

View UMEDIC GROUP BERHAD Historical chart here